Rilonacept shows therapeutic potential for recurrent pericarditis
21 Dec 2020
byAudrey Abella
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.